This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2021 Nov;34(11):2087-2088.

doi: 10.1038/s41379-021-00809-7. Epub 2021 Apr 12.

CTNNB1 mutations in papillary thyroid carcinoma with prominent myofibroblastic stromal component

Abdallah Roukain¹, Gerasimos P Sykiotis²

Affiliations

Affiliations

¹ Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. abdallah.roukain@chuv.ch.
² Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. gerasimos.sykiotis@chuv.ch.

PMID: 33846546
DOI: 10.1038/s41379-021-00809-7

Free article

CTNNB1 mutations in papillary thyroid carcinoma with prominent myofibroblastic stromal component

Abdallah Roukain et al. Mod Pathol. 2021 Nov.

Free article

. 2021 Nov;34(11):2087-2088.

doi: 10.1038/s41379-021-00809-7. Epub 2021 Apr 12.

Authors

Abdallah Roukain¹, Gerasimos P Sykiotis²

Affiliations

¹ Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. abdallah.roukain@chuv.ch.
² Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland. gerasimos.sykiotis@chuv.ch.

PMID: 33846546
DOI: 10.1038/s41379-021-00809-7

No abstract available

PubMed Disclaimer

Similar articles

Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases.
Suster D, Michal M, Nishino M, Piana S, Bongiovanni M, Blatnik O, Hájková V, Ptáková N, Michal M, Suster S. Suster D, et al. Mod Pathol. 2020 Sep;33(9):1702-1711. doi: 10.1038/s41379-020-0539-7. Epub 2020 Apr 14. Mod Pathol. 2020. PMID: 32291398
High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
Išić Denčić T, Bartolome A, Šelemetjev S, Đorić I, Tatić S, Živaljević V, Cvejić D. Išić Denčić T, et al. Exp Mol Pathol. 2018 Oct;105(2):181-189. doi: 10.1016/j.yexmp.2018.08.001. Epub 2018 Aug 2. Exp Mol Pathol. 2018. PMID: 30077672
SOX11 expression in a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma containing BRAF c.1799_1801delTGA and CTNNB1 c.133T>C mutations.
Wong SBJ, Nga ME, Michal M, Vanecek T, Seet JE, Petersson F. Wong SBJ, et al. Virchows Arch. 2019 Oct;475(4):519-525. doi: 10.1007/s00428-019-02619-4. Epub 2019 Jul 20. Virchows Arch. 2019. PMID: 31327063
Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
Jung CK, Kim Y, Jeon S, Jo K, Lee S, Bae JS. Jung CK, et al. Hum Pathol. 2018 Nov;81:9-17. doi: 10.1016/j.humpath.2018.04.018. Epub 2018 May 1. Hum Pathol. 2018. PMID: 29723601 Review.
[Histopatological and molecular genetic characteristics of clinically aggressive variants of papillary thyroid carcinoma].
Bogolyubova AV, Abrosimov AY, Selivanova LS, Belousov PV. Bogolyubova AV, et al. Arkh Patol. 2019;81(1):46-51. doi: 10.17116/patol20198101146. Arkh Patol. 2019. PMID: 30830105 Review. Russian.

See all similar articles

Cited by

Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis: Review of Published Cases.
Roukain A, La Rosa S, Bongiovanni M, Nicod Lalonde M, Cristina V, Montemurro M, Cochet S, Luquain A, Kopp PA, Sykiotis GP. Roukain A, et al. Cancers (Basel). 2021 Sep 6;13(17):4482. doi: 10.3390/cancers13174482. Cancers (Basel). 2021. PMID: 34503292 Free PMC article. Review.
Circular RNAs: characteristics, functions, mechanisms, and potential applications in thyroid cancer.
Wu M, Yuan H, Zou W, Xu S, Liu S, Gao Q, Guo Q, Han Y, An X. Wu M, et al. Clin Transl Oncol. 2024 Apr;26(4):808-824. doi: 10.1007/s12094-023-03324-0. Epub 2023 Oct 21. Clin Transl Oncol. 2024. PMID: 37864677 Review.

References

1. Suster D, Michal M, Nishino M, Piana S, Bongiovanni M, Blatnik O, et al. Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases. Mod Pathol. 2020;33:1702–11. - DOI
1. Crago AM, Chmielecki J, Rosenberg M, O’Connor R, Byrne C, Wilder FG, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54:606–15. - DOI
1. Trautmann M, Rehkamper J, Gevensleben H, Becker J, Wardelmann E, Hartmann W, et al. Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis—a systematic analysis of 204 cases. Sci Rep. 2020;10:3368. - DOI
1. Rebecchini C, Nobile A, Piana S, Sarro R, Bisig B, Gerasimos SP, et al. Papillary thyroid carcinoma with nodular fasciitis-like stroma and beta-catenin mutations should be renamed papillary thyroid carcinoma with desmoid-type fibromatosis. Mod Pathol. 2017;30:236–45. - DOI
1. Takada N, Mussazhanova Z, Hirokawa M, Nakashima M, Miyauchi A. Immunohistochemical and molecular analyses focusing on mesenchymal cells in papillary thyroid carcinoma with desmoid-type fibromatosis. Pathobiology. 2018;85:300–3. - DOI

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal